Since the establishment of the critical role of BMPR‐II loss of function in the pathogenesis of PAH, significant efforts have focused on understanding how BMPR‐II mutations and dysfunction cause PAH and how to target such a pathway to treat PAH. The gene discussed is BMPR2; the disease is pulmonary arterial hypertension.